Navigation Links
SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
Date:5/16/2008

- Canadian Biotechnology Company's partner Aqua Bounty to scale back

commitment to immunostimulatory feed additive program -

TSX symbol: SBS

CALGARY, May 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that its joint development partner on the ImmunoSphere(TM) shrimp feed additive program, Aqua Bounty Technologies Inc. (AIM: ABTX), has announced that it intends to scale back marketing and registration efforts on its first generation shrimp feed additive, IMS. SemBioSys is developing a second generation shrimp feed additive product in safflower, ImmunoSphere(TM), that has the potential to significantly reduce the manufacturing costs of the feed additive.

"With this recent decision from Aqua Bounty related to its first generation shrimp feed additive product, we intend to evaluate the impact it has for our second generation product, ImmunoSphere(TM)," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Our safflower-derived ImmunoSphere(TM) product offers a significant reduction to the cost of production of immunostimulatory feed additives. We intend to evaluate all of the available options prior to committing to next steps with this product which targets a large potential market that has a significant unmet need."

The global shrimp industry represents an US$18 billion market. One of the major challenges faced by commercial shrimp production is disease outbreak which cost the shrimp aquaculture industry more than US$3 billion per year. Immunostimulatory feed additives, like ImmunoSphere(TM), are designed to provide prophylactic protection to shrimp production.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More information is available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... MONMOUTH JUNCTION, N.J. , Feb. 4, 2016 ... critical care immunotherapy leader commercializing its flagship CytoSorb® ... and cardiac surgery patients around the world, announced ... PhD, will present at the Source Capital Group,s ... overview and update on the company.  ...
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), ... for its second quarter ended December 31, 2015. ... quarter of fiscal 2016 increased 2 percent compared to the comparable ... quarter of fiscal 2016 was $35.0 million, or $0.93 per diluted ... net income for the first quarter of fiscal 2016 grew 9 ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):